ArticleOxidative medicine and cellular longevity2016
Metforminium Decavanadate as a Potential Metallopharmaceutical Drug for the Treatment of Diabetes Mellitus.
Article in Oxidative medicine and cellular longevity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 62 citations in OpenAlex.
- Gadolinium Orthovanadate Nanoparticles Normalizes Glycemia, Insulin Resistance, and Glucose Tolerance in Rats with Experimental Type 2 Diabetes Mellitus.Biological trace element research · 2026Article
- Enhanced Therapeutic Efficacy of Lispro-Protamine Insulin Via Vanadate and Decavanadate Functionalization in a Type 1 Diabetes Murine Model.Biological trace element research · 2026Article
- Decavanadate Compound Displays In Vitro and In Vivo Antitumor Effect on Melanoma Models.Bioinorganic chemistry and applications · 2025Article
- A Non-Toxic Binuclear Vanadium(IV) Complex as Insulin Adjuvant Improves the Glycemic Control in Streptozotocin-Induced Diabetic Rats.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Chronic Variable Stress and Cafeteria Diet Combination Exacerbate Microglia andInternational journal of molecular sciences · 2024Article
- Repurposing Therapeutic Drugs Complexed to Vanadium in Cancer.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Hepatic Insulin Resistance Model in the Male Wistar Rat Using Exogenous Insulin Glargine Administration.Metabolites · 2023Article
- Biological Consequences of Vanadium Effects on Formation of Reactive Oxygen Species and Lipid Peroxidation.International journal of molecular sciences · 2023Review
- Polyoxometalates Impact as Anticancer Agents.International journal of molecular sciences · 2023Review
- Biological Properties of Transition Metal Complexes with Metformin and Its Analogues.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Editorial: Emerging polyoxometalates with biological, biomedical, and health applications.Frontiers in chemistry · 2022Article
- Tris(2-Pyridylmethylamine)V(O)Frontiers in chemistry · 2022Article
- Sodium metavanadate treatment improves glycogen levels in multiple tissues in a model of metabolic syndrome caused by chronic cadmium exposure in Wistar rats.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2021Article
- Rationalizing the Decavanadate(V) and Oxidovanadium(IV) Binding to G-Actin and the Competition with Decaniobate(V) and ATP.Inorganic chemistry · 2021Article
- Vanadium-dependent activation of glucose transport in adipocytes by catecholamines is not mediatedWorld journal of diabetes · 2020Article
- Vanadium in Biological Action: Chemical, Pharmacological Aspects, and Metabolic Implications in Diabetes Mellitus.Biological trace element research · 2019Review
- The P-type ATPase inhibiting potential of polyoxotungstates.Metallomics : integrated biometal science · 2018Article
- The antibacterial activity of polyoxometalates: structures, antibiotic effects and future perspectives.Chemical communications (Cambridge, England) · 2018Article
- Decavanadate Salts of Cytosine and Metformin: A Combined Experimental-Theoretical Study of Potential Metallodrugs Against Diabetes and Cancer.Frontiers in chemistry · 2018Article
- Pharmacological and Toxicological Threshold of Bisammonium Tetrakis 4-(Bioinorganic chemistry and applications · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New potential drugs based on vanadium are being developed as possible treatments for diabetes mellitus (DM) and its complications. In this regard, our working group developed metforminium decavanadate (MetfDeca), a compound with hypoglycemic and hypolipidemic properties. MetfDeca was evaluated in models of type 1 and type 2 diabetes mellitus, on male Wistar rats. Alloxan-induction was employed to produce DM1 model, while a hypercaloric-diet was employed to generate DM2 model. Two-month treatments with 3.7 μg (2.5 μM)/300 g/twice a week for DM2 and 7.18 μg (4.8 μM)/300 g/twice a week for DM1 of MetfDeca, respectively, were administered. The resulting pharmacological data showed nontoxicological effects on liver and kidney. At the same time, MetfDeca showed an improvement of carbohydrates and lipids in tissues and serum. MetfDeca treatment was better than the monotherapies with metformin for DM2 and insulin for DM1. Additionally, MetfDeca showed a protective effect on pancreatic beta cells of DM1 rats, suggesting a possible regeneration of these cells, since they recovered their insulin levels. Therefore, MetfDeca could be considered not only as an insulin-mimetic agent, but also as an insulin-enhancing agent. Efforts to elucidate the mechanism of action of this compound are now in progress.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.